UA85373C2 - Слитый протеин регуляторных/аксессорных hіv протеинов - Google Patents

Слитый протеин регуляторных/аксессорных hіv протеинов

Info

Publication number
UA85373C2
UA85373C2 UA20041109408A UA20041109408A UA85373C2 UA 85373 C2 UA85373 C2 UA 85373C2 UA 20041109408 A UA20041109408 A UA 20041109408A UA 20041109408 A UA20041109408 A UA 20041109408A UA 85373 C2 UA85373 C2 UA 85373C2
Authority
UA
Ukraine
Prior art keywords
proteins
fusion protein
nucleic acids
hiv
accessory proteins
Prior art date
Application number
UA20041109408A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пол Хаули
Сонья Лейрер
Ева Фелдер
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of UA85373C2 publication Critical patent/UA85373C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16HIV-1 ; HIV-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к слитому протеину, который содержит аминокислотную последовательность, по крайней мере, четырех HIV протеинов, выбранных из Vif, Vpr, Vpu, Vpx, Rev, Tat и Nef, или производной аминокислотной последовательности одного или более указанных протеинов, где слитый протеин не преобразуется до индивидуальных HIV протеинов, которые имеют естественные N и С концы. Кроме того, изобретение касается нуклеиновых кислот, которые кодируют указанный протеин, векторов, которые содержат указанные нуклеиновые кислоты, и способов получения указанных протеинов. Слитый протеин, нуклеиновые кислоты и векторы применяются как вакцины, по крайней мере, для профилактики HIV инфекций.
UA20041109408A 2002-05-16 2003-05-14 Слитый протеин регуляторных/аксессорных hіv протеинов UA85373C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200754 2002-05-16

Publications (1)

Publication Number Publication Date
UA85373C2 true UA85373C2 (ru) 2009-01-26

Family

ID=29433046

Family Applications (3)

Application Number Title Priority Date Filing Date
UA20041109410A UA82998C2 (ru) 2002-05-16 2003-05-14 Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
UA20041109408A UA85373C2 (ru) 2002-05-16 2003-05-14 Слитый протеин регуляторных/аксессорных hіv протеинов
UAA200811374A UA92788C2 (ru) 2002-05-16 2003-05-14 Слитый протеин регуляторных/аксессорных hiv протеинов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA20041109410A UA82998C2 (ru) 2002-05-16 2003-05-14 Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200811374A UA92788C2 (ru) 2002-05-16 2003-05-14 Слитый протеин регуляторных/аксессорных hiv протеинов

Country Status (23)

Country Link
US (7) US20050222388A1 (ru)
EP (2) EP1506223B1 (ru)
JP (3) JP2006502704A (ru)
KR (4) KR101196178B1 (ru)
CN (3) CN1325512C (ru)
AT (2) ATE310016T1 (ru)
AU (2) AU2003240638B2 (ru)
BR (1) BR0309963A (ru)
CA (1) CA2483640A1 (ru)
CY (1) CY1108638T1 (ru)
DE (2) DE60302356T2 (ru)
DK (2) DK1506223T3 (ru)
EA (1) EA007154B1 (ru)
ES (2) ES2253675T3 (ru)
IL (3) IL164178A0 (ru)
MX (1) MXPA04010683A (ru)
NO (1) NO20045229L (ru)
NZ (2) NZ556144A (ru)
PL (2) PL372092A1 (ru)
PT (1) PT1652857E (ru)
SI (2) SI1506223T1 (ru)
UA (3) UA82998C2 (ru)
WO (1) WO2003097675A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
UA82998C2 (ru) * 2002-05-16 2008-06-10 Бавариан Нордик А/С Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
ATE520708T1 (de) 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
IL296832A (en) * 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
SG193145A1 (en) 2008-07-21 2013-09-30 Taiga Biotechnologies Inc Differentiated anucleated cells and method for preparing the same
DK3339321T3 (da) 2008-08-28 2021-06-21 Taiga Biotechnologies Inc Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
AU2010305030A1 (en) 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
WO2011043830A2 (en) * 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2015192339A1 (zh) * 2014-06-18 2015-12-23 中山大学 一种嵌合载体及其制备方法和应用
CN104130331B (zh) * 2014-06-19 2017-06-06 中山大学 一种抗hiv‑1病毒药物及其制备和应用
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN105330729A (zh) * 2015-11-18 2016-02-17 南京医科大学 一种人类免疫缺陷病毒Vpr蛋白的制备方法
EP3548425B1 (en) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4088697A (en) * 1996-08-26 1998-03-19 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FI105105B (fi) 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
BR0107972A (pt) 2000-01-31 2002-11-05 Smithkline Beecham Biologicals Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
EP2388015A1 (en) * 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
KR100815888B1 (ko) * 2000-07-14 2008-03-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Hiv 보조 단백질을 암호화하는 dna 백신
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82998C2 (ru) * 2002-05-16 2008-06-10 Бавариан Нордик А/С Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті

Also Published As

Publication number Publication date
KR20050010000A (ko) 2005-01-26
ATE310016T1 (de) 2005-12-15
CN1982332A (zh) 2007-06-20
AU2003240638B2 (en) 2008-05-15
DK1506223T3 (da) 2006-04-10
US20120142097A1 (en) 2012-06-07
US8143054B2 (en) 2012-03-27
UA92788C2 (ru) 2010-12-10
ES2313166T3 (es) 2009-03-01
KR101196178B1 (ko) 2012-11-01
EA007154B1 (ru) 2006-08-25
US8389275B2 (en) 2013-03-05
BR0309963A (pt) 2005-02-22
EP1652857B9 (en) 2009-10-14
EA200401504A1 (ru) 2005-04-28
AU2003240638A1 (en) 2003-12-02
US20090280561A1 (en) 2009-11-12
CN1653085A (zh) 2005-08-10
PL372092A1 (en) 2005-07-11
WO2003097675A1 (en) 2003-11-27
US20050222388A1 (en) 2005-10-06
DE60323407D1 (de) 2008-10-16
US8137931B2 (en) 2012-03-20
PL397252A1 (pl) 2012-04-10
KR20120106894A (ko) 2012-09-26
PT1652857E (pt) 2008-12-12
DE60302356D1 (de) 2005-12-22
EP1652857A3 (en) 2007-03-14
KR20110099058A (ko) 2011-09-05
ATE407143T1 (de) 2008-09-15
ES2253675T3 (es) 2006-06-01
NO20045229L (no) 2004-11-29
KR100996330B1 (ko) 2010-11-23
SI1506223T1 (sl) 2006-04-30
EP1652857B1 (en) 2008-09-03
AU2008252074B2 (en) 2012-02-16
JP2010099084A (ja) 2010-05-06
US20100047871A1 (en) 2010-02-25
EP1506223B1 (en) 2005-11-16
CN101108882A (zh) 2008-01-23
IL164178A (en) 2011-01-31
CA2483640A1 (en) 2003-11-27
US8147839B2 (en) 2012-04-03
HK1076822A1 (en) 2006-01-27
IL164178A0 (en) 2005-12-18
JP2006502704A (ja) 2006-01-26
JP2009178165A (ja) 2009-08-13
US20100047268A1 (en) 2010-02-25
US20060257974A1 (en) 2006-11-16
US7569228B2 (en) 2009-08-04
US8435535B2 (en) 2013-05-07
IL197304A0 (en) 2011-07-31
EP1506223A1 (en) 2005-02-16
UA82998C2 (ru) 2008-06-10
NZ556144A (en) 2008-04-30
MXPA04010683A (es) 2005-02-17
CY1108638T1 (el) 2014-04-09
DE60302356T2 (de) 2006-08-03
NZ536499A (en) 2008-04-30
KR20100063126A (ko) 2010-06-10
SI1652857T1 (sl) 2009-02-28
US20120142096A1 (en) 2012-06-07
DK1652857T3 (da) 2009-01-05
AU2008252074A1 (en) 2009-01-08
CN1325512C (zh) 2007-07-11
EP1652857A2 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
IL197304A0 (en) Fusion protein of hiv regulatory/accessory proteins
IL264925A (en) Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
HUP0004896A1 (hu) HIV-1 Tat és/vagy Nef fehérjéket tartalmazó fúziós fehérjék
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
WO2007149491A3 (en) Soluble stabilized trimeric hiv env proteins and uses thereof
ES2013346A6 (es) Metodos para producir secuencias y moleculas de adn recombinante, asi como proteinas t4 solubles.
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
WO2005047483A3 (en) Renta: an hiv immunogen and uses thereof
GB0325011D0 (en) HIV pharmaccines
WO2020144355A3 (fr) Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre
WO2005103302A3 (en) Mutant viral nucleic acids and vaccine containing same
WO2002068464A3 (de) Fusionsprotein zum blocken des hiv nef-proteins